{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estrace",
    "query": {
      "intervention": "Estrace"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 883,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estrace&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T02:13:45.712Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00193271",
      "title": "Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Estramustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2004-08",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2011-05-03",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00193271"
    },
    {
      "nct_id": "NCT06820307",
      "title": "Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Suzetrigine",
          "type": "DRUG"
        },
        {
          "name": "DRSP/EE",
          "type": "DRUG"
        },
        {
          "name": "NGM/EE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-02-25",
      "completion_date": "2025-04-29",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06820307"
    },
    {
      "nct_id": "NCT02761694",
      "title": "Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Vevorisertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2016-06-26",
      "completion_date": "2021-03-10",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 6,
      "location_summary": "Las Vegas, Nevada • Oklahoma City, Oklahoma • Charleston, South Carolina + 3 more",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02761694"
    },
    {
      "nct_id": "NCT00387829",
      "title": "DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Injuries",
        "Adhesions"
      ],
      "interventions": [
        {
          "name": "DuraGen Plus Adhesion Barrier Matrix",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Integra LifeSciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 347,
      "start_date": "2006-10",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2017-09-07",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 36,
      "location_summary": "Mobile, Alabama • Beverly Hills, California • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00387829"
    },
    {
      "nct_id": "NCT04544475",
      "title": "A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Genitourinary Syndrome of Menopause (GSM)"
      ],
      "interventions": [
        {
          "name": "Revaree",
          "type": "DEVICE"
        },
        {
          "name": "Estrace",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 49,
      "start_date": "2021-09-01",
      "completion_date": "2022-10-03",
      "has_results": true,
      "last_update_posted_date": "2023-10-13",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04544475"
    },
    {
      "nct_id": "NCT03685331",
      "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Locally Advanced Breast Cancer",
        "Advanced Breast Cancer",
        "BRCA2 Mutation",
        "BRCA1 Mutation"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2020-10-15",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03685331"
    },
    {
      "nct_id": "NCT00264407",
      "title": "Neural Changes in the Aging Auditory System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Progesterone",
        "Estrogens",
        "Hearing",
        "Psychoacoustics",
        "Auditory Perceptual Disorders"
      ],
      "interventions": [
        {
          "name": "Hormone Replacement Therapy - HRT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "86 Years",
        "sex": "FEMALE",
        "summary": "60 Years to 86 Years · Female only"
      },
      "enrollment_count": 126,
      "start_date": "2001-01",
      "completion_date": "2005-02",
      "has_results": false,
      "last_update_posted_date": "2005-12-12",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 2,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00264407"
    },
    {
      "nct_id": "NCT04551807",
      "title": "Natural Versus Programmed Frozen Embryo Transfer (NatPro)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pregnancy Related",
        "Pre-Eclampsia"
      ],
      "interventions": [
        {
          "name": "Modified natural cycle",
          "type": "PROCEDURE"
        },
        {
          "name": "Programmed cycle",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "JHSPH Center for Clinical Trials",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "41 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 41 Years · Female only"
      },
      "enrollment_count": 788,
      "start_date": "2020-09-16",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Sunnyvale, California • Orange, Connecticut + 12 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "Connecticut"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04551807"
    },
    {
      "nct_id": "NCT00808132",
      "title": "Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Menopause",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "bazedoxifene 20 mg/ conjugated estrogens 0.45 mg",
          "type": "DRUG"
        },
        {
          "name": "bazedoxifene 20 mg/ conjugated estrogens 0.625 mg",
          "type": "DRUG"
        },
        {
          "name": "bazedoxifene 20 mg",
          "type": "DRUG"
        },
        {
          "name": "conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 64 Years · Female only"
      },
      "enrollment_count": 1886,
      "start_date": "2009-01",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 143,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00808132"
    },
    {
      "nct_id": "NCT04856306",
      "title": "Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heavy Menstrual Bleeding",
        "Fibroid Uterus"
      ],
      "interventions": [
        {
          "name": "Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure",
          "type": "OTHER"
        },
        {
          "name": "Elagolix Oral Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Medstar Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 300,
      "start_date": "2021-04-12",
      "completion_date": "2025-08-30",
      "has_results": false,
      "last_update_posted_date": "2022-05-05",
      "last_synced_at": "2026-09-10T02:13:45.712Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04856306"
    }
  ]
}